DNA polymerase θ (POLθ) is a specialized, error-prone DNA polymerase that promotes the repair of DNA double-strand breaks through theta-mediated end joining (TMEJ), an alternative pathway that operates independently of homologous recombination.
Third Arc Bio Inc. has closed a $52 million series A extension to advance its pipeline of multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications.
Biodexa Pharmaceuticals plc has closed an exclusive license agreement with Otsuka Pharmaceutical Co. Ltd. for OPB-171775 (now MTX-240), a phase I-ready molecular glue intended to be developed for the treatment of gastrointestinal stromal tumors (GIST) and potentially additional indications.
Kinoteck Therapeutics Co. Ltd. has discovered nitrogen-containing heterocyclic derivatives acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.
A patent from Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. describes new multi-membered macrocyclic compounds acting as GTPase KRAS G12C, G12V and/or G13D mutant inhibitors.
Researchers from Nirma University in India aimed to discover and develop novel small-molecule telomerase inhibitors derived from known scaffolds with improved efficacy and safety for lung cancer therapy.
Interleukin-12 (IL-12) is a pro-inflammatory cytokine produced by antigen-presenting cells that plays a central role in shaping cell-mediated immune responses. It promotes the activation and effector function of natural killer cells and cytotoxic CD8+ T lymphocytes and drives the differentiation of CD4+ T cells toward a T helper 1 phenotype.
IL-10-based approaches have shown promise in cancer immunotherapy by activating exhausted CD8+ T cells, but severe hematological toxicities have limited their clinical use. Recent strategies aim to harness IL-10’s antitumor effects while reducing these toxicities.
Prelude Therapeutics Inc. has received IND clearance from the FDA for PRT-12396, a mutant-selective JAK2 V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms.
Advancell Pty Ltd. has entered into a collaboration and exclusive licensing agreement with 48Hour Discovery Inc. to develop a novel peptide-based lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need.
RSS
